Northwestern University

Groupon, Inc.

Rishi R Arora

Tihomir Tsankov Georgiev

Michael Chen

Geoffrey Hubert Woo

Robert James Skillington

Mahmudul Arefin Din

Alan Deitch

Jason Ng

Alan Kadish

David E Zembower

Annette Gilchrist

Gary L Aistrup

Provided herein are compositions, methods, and devices for the treatment and prevention of atrial fibrillation (AF) using gene therapy techniques. In particular, oxidative stress (OS) and parasympathetic nervous system signaling are inhibited to prevent and/or reverse the electrical remodeling that underlies AF.

Gene therapy treatment of atrial fibrillation

Disclosed herein are pharmaceutical compositions and methods for inhibiting oxidative stress in a subject having atrial or ventricular arrhythmias, ventricular failure or heart failure. The methods include administering an effective amount of a NOX2 inhibitor agent to the subject, wherein said administering is under conditions such that a level of oxidative stress in myocardial tissue is reduced or eliminated. The pharmaceutical compositions include a NOX2 inhibitor agent.

Inhibition of oxidative stress in atrial fibrillation

Systems, apparatus, methods, and non-transitory media for programmatically grouping consumers are discussed herein. Some embodiments may include a system configured to provide to shared promotion redemptions. The system may include a merchant device with processing circuitry configured to associate multiple consumer accounts with a point-of-sale order. Based on receiving redemption data from a consumer device associated with one of the consumer accounts, the system may be further configured to allow the consumer device to share a selected promotion. For example, the system may determine payment share amounts for each consumer account based on a transaction price of the point-of-sale order and the redemption value of the promotion selected for shared redemption.

Systems and methods for providing shared promotion redemptions

Medical devices comprising applicators that present a microneedle array and a separate electroporation array configured to simultaneously contact a tissue surface, a fluidic system connected to the microneedle array, and an electronic system connected to the electroporation array, for the coordinated delivery of a fluid biologic and electroporation energy to a tissue.

Targeted delivery of biologic therapeutic agents

The invention relates generally to systems and devices for material delivery, energy delivery, and/or monitoring electrophysiological activity, and method of use thereof. In particular, the present invention provides devices and systems, and methods of use thereof, configured to deliver therapeutic compositions, to provide electroporation and/or sonoporation to increase therapeutic efficiency, and to monitor electrophysiological activity, for example, before and after treatment.

Devices for material delivery, electroporation, sonoporation, and/or monitoring electrophysiological activity

The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.

Compositions and methods for treating or preventing atrial fibrillation

The invention relates generally to methods of detecting reactive oxygen species (ROS) in cardiac tissue and treatment modalities for ablating ROS-associated tissue in cardiac disease. The methods rely upon targeting ROS-associated cardiac tissue for ablation and/or gene therapy in a subject using analytical tools based upon a plurality of recorded atrial EGMs for a tissue to assess ROS content and underlying AF organization as a function of ROS blockade conditions.

Contribution of oxidative stress to AF electrograms

A method of targeting fibrosis or autonomic nerve tissue for ablation in a subject is provided. The method includes performing at least one EGM analysis of a plurality of recorded atrial EGMs for a tissue in a region suspected of having fibrosis or autonomic nerve tissue. With regard to targeting fibrosis for ablation, the method includes determining one or more correlations of at least one AF EGM characteristic to a region having fibrosis from the plurality of recorded atrial EGMs for the tissue and determining whether the tissue contains dense fibrosis that would preclude effective ablation of the analysis region of the tissue. With regard to targeting autonomic nerve for ablation, the method includes determining whether one or more significant changes in EGM characteristics with autonomic blockade exist that would indicate the need to perform ablation of the analysis region of the tissue.

Using intracardiac electrograms to predict location of fibrosis and autonomic nerves in the heart

The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing AF fibrosis in a subject, and if so, methods of reducing AF fibrosis in a subject using gene therapy with a dominant negative TGF-&#x3b2; R2 cDNA expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating AF fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method.

Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)

The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation.

Growing community of inventors

Chicago, IL, United States of America

Rishi R Arora